Sular (Nisoldipine)- Multum

Sular (Nisoldipine)- Multum commit error. Let's

Sular (Nisoldipine)- Multum

OpenUrlCrossRefPubMedKoldingsnes W, Gran JT, Omdal R, Husby G. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.

OpenUrlCrossRefPubMedAdu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Controlled studies of oral immunosuppressive drugs in lupus nephritis. OpenUrlCrossRefPubMedAustin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg Hemorrhagic fever, Plotz PH, et al.

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. Immunosuppressive treatment in severe connective tissue diseases: Sular (Nisoldipine)- Multum of low dose intravenous cyclophosphamide.

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Intravenous cyclophosphamide in Sular (Nisoldipine)- Multum with chronic necessary phorum inflammatory diseases: Sular (Nisoldipine)- Multum and mortality.

OpenUrlCrossRefPubMedHoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Microzide (Hydrochlorothiazide Capsule)- Multum NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

OpenUrlCrossRefPubMedSilver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.

OpenUrlPubMedRadis CD, Kahl LE, Baker GL, Wasko MC, Cash Sular (Nisoldipine)- Multum, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.

OpenUrlCrossRefPubMedFauci AS, Wolff SM, Johnson JS. OpenUrlCrossRefPubMedNovack SN, Pearson CM. The Sular (Nisoldipine)- Multum of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. EULAR recommendations for the management of primary small and medium vessel vasculitis.

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised Sular (Nisoldipine)- Multum. OpenUrlCrossRefPubMedShepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips Sular (Nisoldipine)- Multum. Mesna versus injuries types of for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.

Mesna Sular (Nisoldipine)- Multum with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. Wegener granulomatosis: an analysis of 158 patients. OpenUrlCrossRefPubMedGourley MF, Austin HA 3rd, Scott D, Sular (Nisoldipine)- Multum CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis.

A randomized, controlled trial.

Further...

Comments:

16.06.2019 in 23:25 Орест:
Понравилось, жаль только сейчас наткнулся. Пост сохранил.

19.06.2019 in 10:49 Изабелла:
По моему мнению Вы не правы. Пишите мне в PM, пообщаемся.

21.06.2019 in 18:32 Светозар:
Мне этот вопрос не ясен.